Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin for ED Treatment of Complicated Skin Infections
NCT01549613Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- May 2012
- Primary completion
- Jul 2013
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daptomycin in Skin and Skin Structure Infection (SSSI) and cellulitis (2 arms), sponsored by University of Cincinnati. Primary endpoint: Satisfaction of Discharge Criteria at 30 days. Started May 2012; status: completed.
02
Drugs
daptomycin
03
Conditions
Skin and Skin Structure Infection (SSSI)cellulitis
Beyond the preview
Go deeper on NCT01549613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01549613.